Respiratory viruses have plagued humanity for millennia. The latest respiratory virus to
emerge—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—has caused the …

Background Clinical benefit of molnupiravir (MPV) in coronavirus disease 2019 (COVID-19)–
infected subpopulations is unclear. Methods We used a matched cohort study design to …

We agree with the authors on the evident advantage provided by non-pharmaceutical
interventions (facial masking, social distancing, and improved ventilation) in lowering SARS …

The ongoing COVID-19 pandemic continues to present surges in infections demonstrating
the persistent threat posed by COVID-19. Amidst efforts to develop effective treatments for …

As COVID-19 pandemic continues to escalate, hospitals around the world confront with the
need to attend an increasing number of patients. Therefore, we read with much interest the …

TO THE EDITOR—We would like to share ideas on the publication “Absolute and Relative
Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and …

Abstract Background Coronavirus disease 2019 (COVID-19) has a heterogeneous outcome
in individuals from remaining asymptomatic to death. In a majority of cases, mild symptoms …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

Correspondence 766 www. thelancet. com/infection Vol 21 June 2021 for non-
bronchoalveolar lavage biomarkers, which have not been cleared or validated. Although this …

The first case of SARS-CoV-2 infection in United States was confirmed on January 19, 2020,
in a man who had returned home to Snohomish County, Washington on January 15, 2020 …